NCCN Guidelines. Chronic lymphocytic leukemia/small lymphocytic lymphoma; Version 3.2025. https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf. Accessed Aug 2025.

Wendtner CM, Al-Sawaf O, Binder M, et al. Chronic lymphocytic leukemia (CLL). https://www.onkopedia.com/en/onkopedia/guidelines/chronic-lymphocytic-leukemia-cll/@@guideline/html/index.html. Accessed Oct 2025.

Bussot L, De Guibert S, Dilhuydy MS, et al. Recommandations FILO-LYSA 2025 algorithmes de prise en charge des patients atteints de LLC. https://www.filo-leucemie.org/upload/files/LLC-Recommandations_FILO_2025.pdf. Accessed Oct 2025.

Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745–60.

Article  CAS  PubMed  Google Scholar 

Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023;329:918–32.

Article  CAS  PubMed  Google Scholar 

Eichhorst B, Ghia P, Niemann CU, et al. ESMO clinical practice guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024;35:762–8.

Article  CAS  PubMed  Google Scholar 

Al-Sawaf O, Robrecht S, Zhang C, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study. Blood. 2024;144:1924–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Furstenau M, Kater AP, Robrecht S, et al. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2024;25:744–59.

Article  PubMed  Google Scholar 

Munir T, Cairns DA, Bloor A, et al. Chronic lymphocytic leukemia therapy guided by measurable residual disease. N Engl J Med. 2024;390:326–37.

Article  CAS  PubMed  Google Scholar 

Al-Sawaf O, Stumpf J, Zhang C, et al. Fixed-duration versus continuous treatment for chronic lymphocytic leukemia. N Engl J Med. 2026;394(11):1084–96.

Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34:787–98.

Article  CAS  PubMed  Google Scholar 

Byrd JC, Furman RR, Coutre SE, et al. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC-1102 study. Clin Cancer Res. 2020;26:3918–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Munir T, Brown JR, O’Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131:1910–9.

Article  PubMed  PubMed Central  Google Scholar 

Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103:874–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Winqvist M, Andersson PO, Asklid A, et al. Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort. Haematologica. 2019;104:e208–10.

Article  CAS  PubMed  Google Scholar 

Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown JR, Eichhorst B, Lamanna N, et al. Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE. Blood. 2024;144:2706–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shadman M, Munir T, Robak T, et al. Zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: median 5-year follow-up of SEQUOIA. J Clin Oncol. 2025;43:780–7.

Article  CAS  PubMed  Google Scholar 

Guo Y, Liu Y, Hu N, et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton’s tyrosine kinase. J Med Chem. 2019;62:7923–40.

Article  CAS  PubMed  Google Scholar 

Tam CS, Trotman J, Opat S, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134:851–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tam CS, Ou YC, Trotman J, Opat S. Clinical pharmacology and PK/PD translation of the second-generation Bruton’s tyrosine kinase inhibitor, zanubrutinib. Expert Rev Clin Pharmacol. 2021;14:1329–44.

Article  CAS  PubMed  Google Scholar 

Kaptein A, de Bruin G, Emmelot-van Hoek M, et al. Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies. Blood. 2018;132:1871.

Article  Google Scholar 

McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124:3829–30.

Article  CAS  PubMed  Google Scholar 

Pellegrini L, Novak U, Andres M, Suter T, Nagler M. Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;159:103238.

Article  PubMed  Google Scholar 

Xiao L, Salem JE, Clauss S, et al. Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase. Circulation. 2020;142:2443–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133:1298–307.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown JR, Ghia P, Jurczak W, et al. Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database. Haematologica. 2024;109:2277–83.

CAS  PubMed  PubMed Central  Google Scholar 

Ou YC, Tang Z, Novotny W, et al. Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma. Leuk Lymphoma. 2021;62:2612–24.

Article  CAS  PubMed  Google Scholar 

Cull G, Burger JA, Opat S, et al. Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. Br J Haematol. 2022;196:1209–18.

Article  CAS  PubMed  Google Scholar 

Tam CS, Opat SS, Merriman EG, et al. Deep and sustained responses in patients with CLL treated with zanubrutinib or zanubrutinib + obinutuzumab in phase 1/2 AU-003 and phase 1b GA-101 studies: a report from the zanubrutinib extension study. Blood. 2024;144:3255–7.

Article  Google Scholar 

Xu W, Yang S, Tam CS, et al. Zanubrutinib monotherapy for naïve and relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: a pooled analysis of three studies. Adv Ther. 2022;39:4250–65.

Article  CAS  PubMed  Google Scholar 

Xu W, Yang S, Zhou K, et al. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. J Hematol Oncol. 2020;13:48.

Article  CAS